PROTEINA, a leading proteomics company, has announced a collaboration with Emory University School of Medicine in Atlanta to initiate global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. This groundbreaking technology, known as “SPID,” enables highly sensitive detection of protein-protein interaction (PPI) complexes, specifically targeting the BCL2 family of proteins.
The focus of this clinical validation is to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML) using PPI PathFinder BCL2 Dx. This will provide clinicians with valuable insights for more effective prescribing of the widely used BCL2-targeted cancer drug, Venetoclax.
Emory University School of Medicine boasts a renowned research team led by Professor Janghee Woo. Driven by a commitment to improving clinical outcomes for hematological malignancies, Dr. Woo’s team will analyze several hundred AML samples using PPI PathFinder BCL2 Dx to validate its clinical efficacy. The ultimate goal is to uncover molecular intricacies of the disease and identify biomarkers linked to therapeutic response.
Dr. Janghee Woo expressed optimism about the partnership, stating that it will not only validate the clinical efficacy of PPI PathFinder but will also enable collaboration across various fields. This collaboration aims to expand the application of Venetoclax and explore its potential indications in other areas.
Following successful domestic clinical validation in South Korea, PROTEINA is excited about this large-scale clinical validation in the United States. CEO Tae-Young Yoon expressed the company’s commitment to completing the validation process diligently as they take the first step towards widespread use of the PROTEINA SPID platform.
In addition to advancing the field of proteomics, PROTEINA aims to enhance the technological competitiveness of PPI PathFinder and the SPID platform through this collaborative project. Based on the results of the clinical study, the company plans to supply the solution to overseas labs certified by the Clinical Laboratory Improvement Amendments (CLIA).
PROTEINA, founded in Seoul in 2015, serves top pharmaceutical companies and academic institutions globally with its innovative SPID technology. With collaborations across Europe and North America, the company is dedicated to advancing drug development and proteomic research, thereby supporting modern healthcare solutions.
For further information, please contact:
Jason Sang Hyun Park
Business Development Manager
Phone: (+82)02-6959-9489
Email: [email protected]
Source: [Business Wire](https://www.businesswire.com/news/home/20240428101218/en/)
PROTEINA’s recent collaboration with Emory University School of Medicine to conduct global clinical validation of its PPI PathFinder BCL2 Dx product will have several impacts on the market and the field of proteomics.
Market Trends:
1. Growing Demand for Personalized Medicine: The collaboration highlights the increasing trend towards personalized medicine, where treatments are tailored based on individual patients’ biomarkers. The validation of PPI PathFinder BCL2 Dx can provide clinicians with valuable insights to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML) and improve prescribing of BCL2-targeted cancer drugs like Venetoclax.
2. Advancements in Proteomics: This collaboration underscores the advancements in proteomics, particularly in the detection of protein-protein interactions (PPI). The SPID technology developed by PROTEINA enables highly sensitive detection of PPI complexes, specifically targeting the BCL2 family of proteins.
Forecasts:
1. Increased Adoption of PPI PathFinder BCL2 Dx: Following successful domestic clinical validation in South Korea, the global clinical validation in collaboration with Emory University School of Medicine is expected to lead to increased adoption of PPI PathFinder BCL2 Dx in the United States and other regions. This validation will provide evidence of its clinical efficacy and enhance its market acceptance.
2. Expansion of Venetoclax Applications: The collaboration also aims to explore the potential indications of Venetoclax beyond AML. By analyzing molecular intricacies of the disease and identifying biomarkers linked to therapeutic response, there is a possibility of expanding the applications of Venetoclax to other areas of oncology or related fields.
Key Challenges or Controversies:
1. Clinical Validation and Regulatory Approval: Clinical validation is a crucial step in establishing the clinical efficacy and safety of a diagnostic product. PROTEINA will need to navigate the challenges associated with conducting a large-scale clinical study, gathering sufficient evidence, and obtaining regulatory approvals such as certification by the Clinical Laboratory Improvement Amendments (CLIA) for overseas labs.
2. Competitiveness in the Proteomics Market: PROTEINA aims to enhance the technological competitiveness of PPI PathFinder and the SPID platform through this collaborative project. However, the field of proteomics is highly competitive, with several companies and academic institutions working on similar technologies and tools. PROTEINA will need to stay ahead to maintain its market position.
Advantages:
1. Enhanced Precision and Treatment Decision-making: The clinical validation of PPI PathFinder BCL2 Dx can provide clinicians with highly sensitive information about protein-protein interaction complexes. This can help guide treatment decisions and improve patient outcomes by predicting drug responsiveness and personalizing treatment approaches.
2. Expanded Collaboration and Knowledge Sharing: The collaboration between PROTEINA and Emory University School of Medicine facilitates collaboration across various fields. The partnership enables the sharing of expertise and resources, fostering advancements in proteomic research, and potentially leading to new discoveries in molecular intricacies and therapeutic response.
For more information about PROTEINA and the collaboration with Emory University School of Medicine, you can visit their official website: PROTEINA.